Phase 1

Enrolling
Advanced Hematologic Malignancies
LY3410738
Enrolling
Advanced Solid Tumors
LY3410738

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.